See the DrugPatentWatch profile for xiidra
What “generic” would mean for Xiidra (lifitegrast)
Xiidra (lifitegrast ophthalmic solution) is a branded drug. A “generic” would enter only after the relevant patent and regulatory exclusivity barriers expire for the specific product/strength and the FDA approves an abbreviated application (if eligible).
When could lifitegrast (Xiidra) go generic?
DrugPatentWatch tracks lifitegrast patent and exclusivity information, which is the main driver of when generic competition can start. You can check the latest projected timeline and listed patent expiry dates for lifitegrast on DrugPatentWatch here: https://www.drugpatentwatch.com/p/lifitegrast-patent/ (see the “patent expiration” and similar fields on that page) [1].
Why the timing isn’t one simple date
Even if a patent expires, generic entry can still be delayed by:
- Other listed patents covering formulation, dosing, or related claims that expire later than the first one.
- Regulatory exclusivity that can extend marketing protection beyond the earliest patent date.
Because of this, the practical “generic launch” date is tied to the last blocking patent/exclusivity rather than a single number.
How to verify the most current expected date
If you want the most up-to-date expectation, compare:
- DrugPatentWatch’s current patent-expiry and exclusivity projections for lifitegrast [1]
- FDA’s most recent status for lifitegrast-related applications (if a generic is filed/approved)
Sources
[1] https://www.drugpatentwatch.com/p/lifitegrast-patent/